Insider Buying: Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases 30,000 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) CEO Daniel R. Passeri acquired 30,000 shares of Cue Biopharma stock in a transaction that occurred on Monday, December 16th. The stock was acquired at an average price of $1.03 per share, with a total value of $30,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 164,578 shares in the company, valued at $169,515.34. This represents a 22.29 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Cue Biopharma Stock Performance

Shares of Cue Biopharma stock traded up $0.01 during trading hours on Wednesday, reaching $1.07. 451,012 shares of the stock traded hands, compared to its average volume of 453,450. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.05. Cue Biopharma, Inc. has a one year low of $0.45 and a one year high of $3.20. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $67.78 million, a price-to-earnings ratio of -1.19 and a beta of 1.66.

Institutional Trading of Cue Biopharma

Hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP boosted its position in shares of Cue Biopharma by 5.1% in the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company's stock worth $221,000 after purchasing an additional 14,104 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Cue Biopharma during the 2nd quarter valued at approximately $66,000. Good Life Advisors LLC increased its stake in Cue Biopharma by 23.1% in the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company's stock worth $303,000 after acquiring an additional 75,000 shares during the last quarter. Sigma Planning Corp raised its holdings in shares of Cue Biopharma by 50.9% during the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company's stock worth $304,000 after acquiring an additional 135,295 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Cue Biopharma by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,827 shares of the company's stock valued at $385,000 after acquiring an additional 16,371 shares during the last quarter. Institutional investors own 35.04% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus dropped their target price on shares of Cue Biopharma from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday, August 20th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $5.00.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.